FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3168097033> ?p ?o ?g. }

• W3168097033 endingPage "e18590" @default.
• W3168097033 startingPage "e18590" @default.
• W3168097033 abstract "e18590 Background: The use of platinum agents (PT) in neoadjuvant chemotherapy (CTX) for triple negative breast cancer (TNBC) has been debated in research and practice guidelines. In high risk patients, the addition of PT to standard anthracycline and taxane regimens improves pathological complete response without definitive evidence of survival benefit (Korde JCO 2021). Due to PT’s toxicities and unclear benefit in early stage breast cancer, this study aimed to elucidate the real world practice patterns of PT use and overuse in breast cancer patients. Methods: The cohort was defined as women with stage I-III TNBC (ER, PR, and Her2 negative) who received curative intent surgery between 2011-2018. We utilized the Hutchinson Institute for Cancer Outcomes Research (HICOR) database, which links enrollment and claims records from commercial and public health insurance plans with clinical information from Washington state cancer registries (Manohar JACR 2020). We hypothesized there was overuse of PT CTX in this cohort. Overuse was defined as PT use in stage I, in the adjuvant period (NCCN 2020), and in nonstandard CTX regimens (PT use without taxane and anthracycline (NCCN 2020)). Results: Of the 910 women in the cohort, average age was 63, 90% were white, 682 (75%) received CTX, and 36% had commercial insurance, versus 53% with public insurance (Medicare 45%, Medicaid 8%). Of those receiving CTX, 39% received neoadjuvant and 67% adjuvant. Of those receiving CTX, 85 (13%) received PT, and 28 (4%) received PT without anthracycline. Of those receiving PT, 20% had stage I disease, and of those receiving adjuvant CTX, 43 (9%) received PT in the adjuvant period. Conclusions: We found there was overuse and nonstandard use of PT in this real world data. This overuse was demonstrated by the fact that 20% of women receiving PT had low risk stage I disease, and 9% of women receiving adjuvant CTX received PT in the adjuvant period. Additionally, there was nonstandard use, with 4% of women getting CTX receiving PT without anthracycline. Next steps in this research are to evaluate factors influencing overuse and nonstandard use, as well as complication rates with PT use and overuse.[Table: see text]" @default.
• W3168097033 created "2021-06-22" @default.
• W3168097033 creator A5027475930 @default.
• W3168097033 creator A5029049718 @default.
• W3168097033 creator A5034096046 @default.
• W3168097033 creator A5037786255 @default.
• W3168097033 date "2021-05-20" @default.
• W3168097033 modified "2023-10-01" @default.
• W3168097033 title "Practice patterns of platinum chemotherapy use in a population-based cohort of women with nonmetastatic triple-negative breast cancer." @default.
• W3168097033 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e18590" @default.
• W3168097033 hasPublicationYear "2021" @default.
• W3168097033 type Work @default.
• W3168097033 sameAs 3168097033 @default.
• W3168097033 citedByCount "0" @default.
• W3168097033 crossrefType "journal-article" @default.
• W3168097033 hasAuthorship W3168097033A5027475930 @default.
• W3168097033 hasAuthorship W3168097033A5029049718 @default.
• W3168097033 hasAuthorship W3168097033A5034096046 @default.
• W3168097033 hasAuthorship W3168097033A5037786255 @default.
• W3168097033 hasConcept C121608353 @default.
• W3168097033 hasConcept C126322002 @default.
• W3168097033 hasConcept C143998085 @default.
• W3168097033 hasConcept C146357865 @default.
• W3168097033 hasConcept C151730666 @default.
• W3168097033 hasConcept C2776802502 @default.
• W3168097033 hasConcept C2777511904 @default.
• W3168097033 hasConcept C2780110267 @default.
• W3168097033 hasConcept C2908647359 @default.
• W3168097033 hasConcept C29456083 @default.
• W3168097033 hasConcept C530470458 @default.
• W3168097033 hasConcept C71924100 @default.
• W3168097033 hasConcept C72563966 @default.
• W3168097033 hasConcept C86803240 @default.
• W3168097033 hasConcept C99454951 @default.
• W3168097033 hasConceptScore W3168097033C121608353 @default.
• W3168097033 hasConceptScore W3168097033C126322002 @default.
• W3168097033 hasConceptScore W3168097033C143998085 @default.
• W3168097033 hasConceptScore W3168097033C146357865 @default.
• W3168097033 hasConceptScore W3168097033C151730666 @default.
• W3168097033 hasConceptScore W3168097033C2776802502 @default.
• W3168097033 hasConceptScore W3168097033C2777511904 @default.
• W3168097033 hasConceptScore W3168097033C2780110267 @default.
• W3168097033 hasConceptScore W3168097033C2908647359 @default.
• W3168097033 hasConceptScore W3168097033C29456083 @default.
• W3168097033 hasConceptScore W3168097033C530470458 @default.
• W3168097033 hasConceptScore W3168097033C71924100 @default.
• W3168097033 hasConceptScore W3168097033C72563966 @default.
• W3168097033 hasConceptScore W3168097033C86803240 @default.
• W3168097033 hasConceptScore W3168097033C99454951 @default.
• W3168097033 hasIssue "15_suppl" @default.
• W3168097033 hasLocation W31680970331 @default.
• W3168097033 hasOpenAccess W3168097033 @default.
• W3168097033 hasPrimaryLocation W31680970331 @default.
• W3168097033 hasRelatedWork W2134503598 @default.
• W3168097033 hasRelatedWork W2331329572 @default.
• W3168097033 hasRelatedWork W2370967127 @default.
• W3168097033 hasRelatedWork W2783325361 @default.
• W3168097033 hasRelatedWork W3027584404 @default.
• W3168097033 hasRelatedWork W3029013680 @default.
• W3168097033 hasRelatedWork W3033574736 @default.
• W3168097033 hasRelatedWork W3114810959 @default.
• W3168097033 hasRelatedWork W3204491303 @default.
• W3168097033 hasRelatedWork W4311544009 @default.
• W3168097033 hasVolume "39" @default.
• W3168097033 isParatext "false" @default.
• W3168097033 isRetracted "false" @default.
• W3168097033 magId "3168097033" @default.
• W3168097033 workType "article" @default.